- Immunization against measles, mumps & rubella:
- 19-49 years old: SC 0.5mL *1-2 doses
- 2nd dose administered 28 days later for high risk adults
Injection:
≥3.4 log10 CCID50
≥4.2 log10 CCID50
≥3.3 log10 CCID50
- Inject SC into outer aspect of upper arm
- Reconstituted solution should be discarded if not used within 8 hours
Live vaccine
It induces antibody formation
- Arthralgia
- Arthritis
- Fever
- Urticaria
- Rash
- Measles-like rash
- Pruritus
- Injection site reaction
- Headache
- Dizziness
- Malaise
- Irritability
- Hypersensitivity to components/class
- Immunocompromised patients
- HIV infection with CD4 <15% or <200
- Active untreated TB infection
- Acute febrile illness
- Pregnancy
- Belimumab
- Certolizumab pegol
- Ibrutinib
- Ifosfamide
- Ixekizumab
- Lomustine
- Mechlorethamine
- Melphalan
- Methotrexate
- Onasemnogene abeparvovec
- Oxaliplatin
- Procarbazine
- Secukinumab
- Ustekinumab
Drug Status
Availability | Prescription only |
Pregnancy | Contraindicated |
Breastfeeding | Weigh risk vs benefit |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Measles Mumps And Rubella Vaccine | FDC | Injection | 1D, 10D | Serum Institute of India | Sai Pharma |
Priorix | FDC | Injection | 1D | GSK Ltd | GSK Ltd |